Our Pipeline

Our Pipeline

Currently in various stages of development and growth, our product portfolio is built upon botanical compounds that have the potential to address worldwide unmet medical demands.

Human Health Product Portfolio

Indication Table Heading
Crofelemer (tablet formulation) Development table.
Crofelemer (tablet formulation) Development table. Click to learn more
Crofelemer (tablet formulation) Development table. Click to learn more
Crofelemer (tablet formulation) Development table.
Crofelemer Crofelemer (tablet formulation)
Crofelemer in Short Bowel Syndrome development table. Click to Learn More.
NP-300 (Lechlemer)† development table. Click to Learn More.

Animal Health Product Portfolio

Indication Table Heading
Canalevia®-CA1 development table. Click to Learn More.
Intestine Icon

Crofelemer (tablet formulation)

Responsible Jaguar Entity
Napo Pharmaceuticals Logo
Noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy*
Chart indicating that this indication is US approved.
Cancer therapy–related diarrhea (CTD)*

Phase 3 trial ongoing globally

IBS – Diarrhea Predominant (IBS-D)*
Chart indicating that this indication is in Phase 2
Idiopathic/functional diarrhea*
Chart indicating that this indication is in Phase 2
Inflammatory bowel disease (IBD)*
Chart indicating that this indication is in the end of Phase 1

Inflammatory diarrhea,
including COVID-associated diarrhea

Geographic focus of clinical activity: EU and US

Chart indicating that this indication is in the end of the Preclinical phase
Intestine Icon

Crofelemer (liquid formulation)

Responsible Jaguar Entity
Napo Therapeutics Logo
Rare disease: Short Bowel Syndrome with Intestinal Failure (SBS-IF) & Congenital Diarrheal Disorders (CDD)

Geographic focus of clinical activity: EU, US, & Middle East

Chart indicating that this indication is in the middle of Phase 1

SBS-IF is initial focus of Napo Therapeutics for conditional approval; Crofelemer has orphan-drug designation in the US and European Union for SBS

NP-300 (Lechlemer)‡ Icon

NP-300

Responsible Jaguar Entity
Napo Pharmaceuticals Logo
Symptomatic relief of diarrhea from cholera*
Chart indicating that this indication is in the end of the Preclinical phase

Received preclinical services funded by the National Institute of Allergy and Infectious Diseases for toxicity studies

Animal Health Product Portfolio

Canalevia™-CA1 Icon

Canalevia®

Canalevia®-CA1: Chemotherapy-induced diarrhea (CID) in dogs*
Chart indicating that this indication is in the end of the Conditional Approval (US)phase

Received conditional market approval in the US, December 2021

Canalevia®-CA2: Exercise-induced diarrhea (EID) in dogs*
Chart indicating that this indication is in the end of the Product Development phase

Pursuing conditional market approval in the US, expected in Q1 2023

*Geographic focus of clinical activity: US